跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ULTOMIRIS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ULTOMIRIS
Authorized
STANDARD
ULTOMIRIS
Alexion Pharma GmbH
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
e7797f538a6bd2ee
Company
Alexion Pharma GmbH
Type
Standard
Approval Details
Approval Id
e7797f538a6bd2ee
Drug Approval Canada Name
ULTOMIRIS
Product Name
ULTOMIRIS
Status
Marketed
Status Date
2023-04-19
Original Market Date
2023-04-19
Din
02533456
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
90:20.00
Atc Original
L04AJ02 RAVULIZUMAB
Atc Name
l 04 aj 02
Aig Number
0161710002
Company Name
Alexion Pharma GmbH
Company Address
Neuhofstrasse 34, Baar, --, Switzerland, 6340
Company Detail Path
/organization/alexion-pharma-gmbh
Company Information
Pharmaceutical Company Name
Alexion Pharma GmbH
Country Name
Switzerland
Province Name
Zug
City Name
baar,zug,country_ch
Address
Neuhofstrasse 34
Active Ingredients
RAVULIZUMAB
1100 MG / 11 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
e7797f538a6bd2ee
Type
Standard
Back to Health Canada Approvals